JP2012516881A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012516881A5 JP2012516881A5 JP2011548754A JP2011548754A JP2012516881A5 JP 2012516881 A5 JP2012516881 A5 JP 2012516881A5 JP 2011548754 A JP2011548754 A JP 2011548754A JP 2011548754 A JP2011548754 A JP 2011548754A JP 2012516881 A5 JP2012516881 A5 JP 2012516881A5
- Authority
- JP
- Japan
- Prior art keywords
- ylmethyl
- azaspiro
- carbamate
- formula
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 —CH 2 CN Chemical group 0.000 claims description 60
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 9
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000004306 triazinyl group Chemical group 0.000 claims description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 5
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 5
- 125000002971 oxazolyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- HEAHLTGDUHXTTO-UHFFFAOYSA-N 1,3-thiazolidine 1,1-dioxide Chemical compound O=S1(=O)CCNC1 HEAHLTGDUHXTTO-UHFFFAOYSA-N 0.000 claims description 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 2
- FBXGQDUVJBKEAJ-UHFFFAOYSA-N 4h-oxazin-3-one Chemical compound O=C1CC=CON1 FBXGQDUVJBKEAJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 2
- 150000003951 lactams Chemical group 0.000 claims description 2
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 claims description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000006085 pyrrolopyridyl group Chemical group 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 20
- 239000002253 acid Substances 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 9
- 239000002904 solvent Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- AKZWRTCWNXHHFR-PDIZUQLASA-N [(3S)-oxolan-3-yl] N-[(2S,3S)-4-[(5S)-5-benzyl-3-[(2R)-2-carbamoyloxy-2,3-dihydro-1H-inden-1-yl]-4-oxo-3H-pyrrol-5-yl]-3-hydroxy-1-phenylbutan-2-yl]carbamate Chemical compound NC(=O)O[C@@H]1Cc2ccccc2C1C1C=N[C@](C[C@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]2CCOC2)(Cc2ccccc2)C1=O AKZWRTCWNXHHFR-PDIZUQLASA-N 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000010992 reflux Methods 0.000 claims 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 238000006254 arylation reaction Methods 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 239000002621 endocannabinoid Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229910052723 transition metal Inorganic materials 0.000 claims 1
- 150000003624 transition metals Chemical class 0.000 claims 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- LKZKGRRDUWVNSR-UHFFFAOYSA-N oxazepin-3-one Chemical group O=C1NOC=CC=C1 LKZKGRRDUWVNSR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0900493A FR2941696B1 (fr) | 2009-02-05 | 2009-02-05 | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| FR0900493 | 2009-02-05 | ||
| PCT/FR2010/050183 WO2010089510A2 (fr) | 2009-02-05 | 2010-02-04 | Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012516881A JP2012516881A (ja) | 2012-07-26 |
| JP2012516881A5 true JP2012516881A5 (enExample) | 2014-07-17 |
| JP5586632B2 JP5586632B2 (ja) | 2014-09-10 |
Family
ID=41037747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011548754A Expired - Fee Related JP5586632B2 (ja) | 2009-02-05 | 2010-02-04 | ５員の複素環式化合物のアザスピラニル−アルキルカルバメートの誘導体、この調製およびこの治療的使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8889702B2 (enExample) |
| EP (1) | EP2393809B1 (enExample) |
| JP (1) | JP5586632B2 (enExample) |
| KR (1) | KR20110117215A (enExample) |
| CN (1) | CN102369200B (enExample) |
| AR (1) | AR075247A1 (enExample) |
| AU (1) | AU2010212235B2 (enExample) |
| BR (1) | BRPI1007456A2 (enExample) |
| CA (1) | CA2751481C (enExample) |
| CO (1) | CO6362007A2 (enExample) |
| EA (1) | EA201171000A1 (enExample) |
| FR (1) | FR2941696B1 (enExample) |
| IL (1) | IL214390A0 (enExample) |
| MA (1) | MA33104B1 (enExample) |
| MX (1) | MX2011008308A (enExample) |
| SG (1) | SG173557A1 (enExample) |
| TN (1) | TN2011000331A1 (enExample) |
| TW (1) | TW201039823A (enExample) |
| UY (1) | UY32423A (enExample) |
| WO (1) | WO2010089510A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130150346A1 (en) | 2010-01-08 | 2013-06-13 | Quest Ventures Ltd. | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome |
| US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
| ES2620668T3 (es) * | 2012-03-02 | 2017-06-29 | Genentech, Inc. | Derivados de amidas y sulfonamidas amido espirocíclicas |
| JP6099753B2 (ja) * | 2012-10-03 | 2017-03-22 | アドビナス セラピューティクス リミテッド | スピロ環化合物、その組成物及びその医薬応用 |
| US10093646B2 (en) | 2014-01-17 | 2018-10-09 | Novartis Ag | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| ES2699354T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2 |
| ES2805232T3 (es) | 2015-06-19 | 2021-02-11 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| EP3310779B1 (en) | 2015-06-19 | 2019-05-08 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| ES2824576T3 (es) | 2015-06-19 | 2021-05-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| US20190083460A1 (en) * | 2016-03-16 | 2019-03-21 | Zeno Royalties & Milestones, LLC | Analgesic compounds |
| CN109415360B (zh) | 2016-06-14 | 2021-11-02 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| US20190343836A1 (en) | 2017-01-10 | 2019-11-14 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| HRP20241558T1 (hr) | 2017-03-13 | 2025-03-28 | Lundbeck La Jolla Research Center, Inc. | Dvojni inhibitori magl i faah |
| CA3072923A1 (en) | 2017-08-29 | 2019-03-07 | Lundbeck La Jolla Research Center, Inc. | Spirocycle compounds and methods of making and using same |
| US12551478B2 (en) * | 2018-09-27 | 2026-02-17 | Shenzhen Chipscreen Biosciences Co., Ltd. | Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity |
| AU2023264787A1 (en) | 2022-05-04 | 2024-10-31 | H. Lundbeck A/S | Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor. |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE184603T1 (de) | 1991-06-19 | 1999-10-15 | Pfizer | Azaspirochinolone als antibakterielle wirkstoffe |
| US6518423B1 (en) | 1996-08-09 | 2003-02-11 | Eisai Co., Ltd. | Benzopiperidine derivatives |
| KR20010023724A (ko) | 1998-02-19 | 2001-03-26 | 다니구치 미즈오 | 프탈라진 유도체 및 발기기능 부전 치료제 |
| FR2816938B1 (fr) | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
| JP2003246780A (ja) | 2001-12-17 | 2003-09-02 | Eisai Co Ltd | 含窒素芳香環化合物の製造方法 |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| FR2843964B1 (fr) * | 2002-08-29 | 2004-10-01 | Sanofi Synthelabo | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique |
| KR20050088992A (ko) * | 2002-10-07 | 2005-09-07 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 아난드아미드 가수분해 차단을 통한 불안감의 조절 |
| FR2854633B1 (fr) * | 2003-05-07 | 2005-06-24 | Sanofi Synthelabo | Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866885B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique |
| FR2885364B1 (fr) * | 2005-05-03 | 2007-06-29 | Sanofi Aventis Sa | Derives d'alkyl-, alkenyl-et alkynylcarbamates, leur preparation et leur application en therapeutique |
| AU2007277253A1 (en) | 2006-07-24 | 2008-01-31 | Gilead Sciences, Inc. | Bisfuranyl protease inhibitors |
| TW200831080A (en) * | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| FR2934265B1 (fr) * | 2008-07-23 | 2010-07-30 | Sanofi Aventis | Derives de carbamates d'alkylthiazoles, leur preparation et leur application en therapeutique |
| US20100113465A1 (en) * | 2008-10-30 | 2010-05-06 | Pfizer Inc. | 7-azaspiro[3.5]nonane-7-carboxamide compounds |
-
2009
- 2009-02-05 FR FR0900493A patent/FR2941696B1/fr not_active Expired - Fee Related
-
2010
- 2010-02-04 EP EP10708283.6A patent/EP2393809B1/fr active Active
- 2010-02-04 BR BRPI1007456-2A patent/BRPI1007456A2/pt not_active IP Right Cessation
- 2010-02-04 MX MX2011008308A patent/MX2011008308A/es unknown
- 2010-02-04 EA EA201171000A patent/EA201171000A1/ru unknown
- 2010-02-04 AU AU2010212235A patent/AU2010212235B2/en not_active Ceased
- 2010-02-04 KR KR1020117020496A patent/KR20110117215A/ko not_active Withdrawn
- 2010-02-04 MA MA34149A patent/MA33104B1/fr unknown
- 2010-02-04 WO PCT/FR2010/050183 patent/WO2010089510A2/fr not_active Ceased
- 2010-02-04 SG SG2011056462A patent/SG173557A1/en unknown
- 2010-02-04 CN CN201080014506.8A patent/CN102369200B/zh not_active Expired - Fee Related
- 2010-02-04 CA CA2751481A patent/CA2751481C/fr not_active Expired - Fee Related
- 2010-02-04 US US13/145,926 patent/US8889702B2/en not_active Expired - Fee Related
- 2010-02-04 JP JP2011548754A patent/JP5586632B2/ja not_active Expired - Fee Related
- 2010-02-05 AR ARP100100315A patent/AR075247A1/es not_active Application Discontinuation
- 2010-02-05 TW TW099103578A patent/TW201039823A/zh unknown
- 2010-02-05 UY UY0001032423A patent/UY32423A/es not_active Application Discontinuation
-
2011
- 2011-07-05 TN TN2011000331A patent/TN2011000331A1/fr unknown
- 2011-08-01 IL IL214390A patent/IL214390A0/en unknown
- 2011-08-05 CO CO11099134A patent/CO6362007A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012516881A5 (enExample) | ||
| AU2010215269B2 (en) | Tosylate salt of a 5-pyrazolyl-2-pyridone derivative, useful in the treatment of COPD | |
| US9604963B2 (en) | Amino-quinolines as kinase inhibitors | |
| EP2566477B1 (en) | Amino-quinolines as kinase inhibitors | |
| US20120135997A1 (en) | Pharmaceutical composition comprising a lactam or benzenesulfonamide compound | |
| JP2018519323A5 (enExample) | ||
| WO2015085238A1 (en) | Inhibitors of lpxc | |
| JP2017514830A5 (enExample) | ||
| WO2011058763A1 (ja) | アミノリンカーを有するアミノチアジンまたはアミノオキサジン誘導体 | |
| JP2007519695A5 (enExample) | ||
| CA2634676A1 (en) | Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein cetp | |
| US20050032786A1 (en) | 1, 3-benzothiazinone derivatives and use thereof | |
| JP2007524707A5 (enExample) | ||
| JPWO2021023154A5 (enExample) | ||
| JP2013510178A5 (enExample) | ||
| JP2002030084A5 (enExample) | ||
| US20140187592A1 (en) | Nitrogen-containing aromatic heterocyclyl compound | |
| JP2019526546A5 (enExample) | ||
| JP2021500332A5 (enExample) | ||
| JP2007507474A5 (enExample) | ||
| JPWO2016148114A1 (ja) | 酸化ストレス誘導神経細胞死抑制化合物 | |
| JP2020500192A5 (enExample) | ||
| WO2002030920A1 (en) | Benzimidazole compounds, process for producing the same and use thereof | |
| JP2007522111A5 (enExample) | ||
| WO2003106429A1 (ja) | プロドラッグおよびその製造法 |